Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

New Risk Factor Gene For Rheumatoid Arthritis Identified By Researchers
Scientists at The Feinstein Institute for Medical Research and a team of collaborators from across the country have identified a new risk factor gene for rheumatoid arthritis. The paper will be published in Nature Genetics and the finding brings light to the nature of the disease. The gene, dubbed REL, is a member of the NF-íºB family, important transcription factors that have many roles in the body. The NF-íºB family seems to have a big hand in regulating the body"s immune response as well.

VIMPAT (lacosamide) Significantly Improved Partial-onset Seizure Control, Increased Seizure Freedom Rates And Enhanced Patient Function
New pooled clinical data presented at the 28th International Epilepsy Congress (IEC) in Budapest, Hungary showed that VIMPAT® (lacosamide), a new antiepileptic drug (AED) with a novel mode of action,1,2 significantly improved seizure control, increased seizure freedom rates during the maintenance phase and enhanced quality of life and patient function, when used as adjunctive therapy in adult patients with uncontrolled partial-onset seizures.2,3
News of the day
New Drug Application For Exenatide Once Weekly Accepted For Review By FDA
Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) announced that the New Drug Application (NDA) for exenatide once weekly has been accepted for review by the U.S. Food and Drug Administration (FDA).
Mental Health

Frankenman International Ltd Secures FDA Clearance For Its Entire CHEX Range Of Surgical Staplers

Frankenman International Ltd, the manufacturer and supplier of surgical instruments, announced that its entire CHEX™ range of surgical staplers had been granted FDA approval. This development complements the CE and ISO accreditation it has already acquired. FDA approval endorses Frankenman"s commitment to total quality in surgical stapling and wound closure devices, and further validates its position as a trusted alternative supplier in these markets. Having established itself in Europe and many other international markets, Frankenman International Ltd now plans to expand marketing of the CHEX range into Japan, Australia and Korea by the end of 2009. This will enable more patients and hospitals around the world to benefit from its cost-effective range of surgical instruments. "We are delighted to have secured FDA registration as this globally recognised quality mark will further strengthen surgeons" confidence in our CHEX range of surgical staplers and establish Frankenman International as a credible player," comments Lee Edwards, President of International Business at Frankenman International Ltd. "With a well established, professional and successful distribution network in place, we are now concentrating on strategic growth by accelerating our internal and external R & D programmes so that we can bring even more innovative instruments to our customers in the coming years." Frankenman International Ltd.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009